6-K
File 001-15170
NEW VIIV LA FORMULATION POTENTIAL 4-MONTH DOSING
- Filing date
- 05 Mar 2024
- Reporting date
- 05 Mar 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
GSK plc reports
- Company location
- London
GSK plc has filed 6,794 SEC EDGAR filings since 12 Jan 2001
SEC filing history
Showing 676-700 of 1,000 matching filings.
Per page
25
Current page
28
6-K
File 001-15170
TOTAL VOTING RIGHTS
- Filing date
- 01 Mar 2024
- Reporting date
- 01 Mar 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
GSK PUBLISHES ANNUAL REPORT 2023
- Filing date
- 01 Mar 2024
- Reporting date
- 01 Mar 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTORATE CHANGE
- Filing date
- 29 Feb 2024
- Reporting date
- 29 Feb 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
STATEMENT: ZANTAC (RANITIDINE) LITIGATION
- Filing date
- 29 Feb 2024
- Reporting date
- 29 Feb 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 26 Feb 2024
- Reporting date
- 26 Feb 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
GSK ANNOUNCES POSITIVE EAGLE-1 HEADLINE RESULTS
- Filing date
- 26 Feb 2024
- Reporting date
- 26 Feb 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 22 Feb 2024
- Reporting date
- 22 Feb 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
VIIV LAI SUPERIOR TO ORALS IN ADHERENCE-CHALLENGED
- Filing date
- 21 Feb 2024
- Reporting date
- 21 Feb 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 20 Feb 2024
- Reporting date
- 20 Feb 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 15 Feb 2024
- Reporting date
- 15 Feb 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
GSK COMPLETES ACQUISITION OF AIOLOS BIO
- Filing date
- 15 Feb 2024
- Reporting date
- 15 Feb 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
SC 13G/A
File 005-84251
SC 13G/A
- Filing date
- 13 Feb 2024
- Reporting date
- Not listed
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 13 Feb 2024
- Reporting date
- 13 Feb 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 13 Feb 2024
- Reporting date
- 13 Feb 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 13 Feb 2024
- Reporting date
- 13 Feb 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 12 Feb 2024
- Reporting date
- 12 Feb 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 12 Feb 2024
- Reporting date
- 12 Feb 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 12 Feb 2024
- Reporting date
- 12 Feb 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
US FDA FAST TRACK DESIGNATION FOR BEPIROVIRSEN
- Filing date
- 12 Feb 2024
- Reporting date
- 12 Feb 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
SC 13D/A
AMENDMENT TO SC 13D
- Filing date
- 09 Feb 2024
- Reporting date
- Not listed
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
SC 13G/A
AMENDMENT TO FORM SC 13G
- Filing date
- 06 Feb 2024
- Reporting date
- Not listed
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
SC 13G/A
AMENDMENT TO FORM SC 13G
- Filing date
- 06 Feb 2024
- Reporting date
- Not listed
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
FDA ACCEPTS AREXVY FILING FOR ADULTS 50-59 AT RISK
- Filing date
- 06 Feb 2024
- Reporting date
- 06 Feb 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
SHINGRIX 18+ AT RISK CHINA FILING REVIEW ACCEPTED
- Filing date
- 06 Feb 2024
- Reporting date
- 06 Feb 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing